Image

Avextra – die Essenz zeitgemäßer Cannabis-Medizin. Evidenzbasiert.

Image Avextra bringt neuartiges Cannabis Granulat auf den Markt – Neue Perspektive in der Patientenversorgung… Zur Pressemitteilung Image Image Neue Studie zeigt positive Ergebnisse bei der Behandlung von Palliativpatient:innen im Spätstadium mit Cannabis-basierten Arzneimitteln Zur Pressemitteilung der CORAL-Studie Image Bei den Deutschen Schmerz- und Palliativtagen wurden die beiden Studien OCEAN-R und IMPACT vorgestellt Zur Pressemitteilung zur IMPACT Studie Zur Pressemitteilung zur OCEAN-R Studie Image Lernen Sie im Video mit unserem CMO David Reckeweg-Lecompte mehr über die Kultivierung von medizinischem Cannabis und die hochmoderne GMP-Herstellung bei Avextra in Deutschland. Avextra:
Qualität Charge für Charge
zur Video-Übersicht
Image Den Einsatz von cannabisbasierten Arzneimitteln ausweiten durch innovative, rigoros getestete und behördlich zugelassene Produkte. Unsere Mission: mehr Infos Image Das therapeutische Potenzial der Cannabispflanze verstehen und nutzen, für eine Verbesserung der Lebensqualität von Patient:innen. Unsere Vision: mehr Infos

Image

Avextra – the essence
of cannabis-based medicine is evidence.

Image Avextra Launches Novel Cannabis Granulate – A new perspective in patient care… press release Image Image New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines… CORAL study press release Image During the German Pain and Palliative Conference, both the OCEAN-R and IMPACT studies were presented. IMPACT study press release OCEAN-R study press release Image Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar Development of Proprietary THC and CBD Cultivars More Information Start Video Image Image Watch this video with our CMO David Reckeweg-Lecompte to learn more about cultivating medicinal cannabis and Avextra’s state-of-the-art GMP manufacturing facility in Germany. Avextra: quality batch by batch Go to our media section Image To expand the use of cannabis-based medicines through innovative, rigorously tested, and regulatory-approved products. Our mission: Read more Image To understand and use the therapeutic potential of the cannabis plant to improve the quality of life of patients. Our vision: Read more

Image

L’essenza della medicina a base di cannabis

Image Avextra Launches Novel Cannabis Granulate – A new perspective in patient care… press release Image Image New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines… CORAL study press release Image During the German Pain and Palliative Conference, both the OCEAN-R and IMPACT studies were presented. IMPACT study press release OCEAN-R study press release Image  Avextra Portugal presenta un avanzato programma di sviluppo di genetiche per sviluppare varietà con THC e CBD, consolidando un pilastro fondamentale del proprio patrimonio genetico. Sviluppo di varietà con THC e CBD Ulteriori informazioni Avvia il video Image Image Rendere i farmaci a base di cannabis disponibili per un’ampia popolazione di pazienti attraverso lo sviluppo di prodotti innovativi, rigorosamente testati e approvati dalle autorità regolatorie. La nostra mission: Per saperne di più Image Comprendere e utilizzare il potenziale terapeutico della pianta di cannabis per migliorare la qualità della vita dei pazienti. La nostra vision: Per saperne di più

Cannabisbasierte Arzneimittel von Avextra

Prescription Medicines, Clinically Developed

Avextra combines innovative, cannabis‑based prescription medicines with a consistent clinical trial program – for more evidence and safety in patient care across Europe.

Our Mission: 

To harness the therapeutic potential of cannabinoids in order to develop, manufacture, and distribute safe, effective, and regulatory‑approved medicines.

Our Vision: 

To provide significant relief to patients worldwide who suffer from chronic diseases through natural substances.

RESEaRCH & DEVELOPMENT

Image

What differentiates Avextra from the rest?

  • We invest one-third of our total budget in research and development
  • We are focused on expanding the evidence base for therapy with cannabis-based medicines
  • Ensure the efficacy and quality of our products
  • Innovation is part of our DNA
Image

Avextra‘s clinical trials and observational studies

Here you can find out more about Avextra's clinical program and the ongoing studies.

Image

We are Specialists for Plant-Based Medicines

Patients in focus: Patients do not suffer from their illnesses alone but also from the symptoms and burdens of coping with serious illness. The goal of our research is to develop cannabis-based products that have proven effective in relieving symptoms.

Image

VaLUE CHaIN

Complete control over the full value chain

Because cannabis has historically not been cultivated at scale for pharmaceutical production, developing cannabis-based medicines that comply fully with EU quality standards, requires an investment in the full production value chain

Our best guarantee for reliable and secure supply for our pharmaceutical production

Image

EXPERT aREA

Image

Service, Information and Documentation for Healthcare Professionals

Expert Area for Physicians

  • Applications and Forms
  • scientific publications

Expert Area for Pharmacists

  • Availability of Products
  • Identity Verification
  • Application for prescription
Image
Image

Memberships

Image
Image
VCA - ASSOCIATION OF CANNABIS SUPPLYING PHARMACIES E.V.

The VCA is the professional association for pharmacies supplying cannabis in Germany. It is focused on developing competence, offers further education and promotes the exchange of content between pharmacists, industry, science and politics. The declared goal of the VCA is to ensure an efficient and affordable supply of medical cannabis to patients in Germany.

Image

Cooperation Partners

Image
EN